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Variation in survival after diagnosis of breast cancer in
Switzerland
Abstract
BACKGROUND: Survival after diagnosis of cancer is a key criterion for cancer control. Major survival
differences between time periods and countries have been reported by the EUROCARE studies. We
investigated whether similar differences by period and region existed in Switzerland. METHODS:
Survival of 11,376 cases of primary invasive female breast cancer diagnosed between 1988 and 1997
and registered in seven Swiss cancer registries covering a population of 3.5 million was analysed.
RESULTS: Comparing the two periods 1988-1992 and 1993-1997, age-standardized 5 year relative
survival improved globally from 77% to 81%. Furthermore, multivariate analysis adjusting for age,
tumour size and nodal involvement identified regional survival differences. Survival was lowest in the
rural parts of German-speaking eastern Switzerland and highest in urbanised regions of the Latin- and
German-speaking northwestern parts of the country. CONCLUSIONS: This study confirms that survival
differences are present even in a small and affluent, but culturally diverse, country like Switzerland,
raising the issue of heterogeneity in access to care and quality of treatment.
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Background: Survival after diagnosis of cancer is a key criterion for cancer control. Major survival
differences between time periods and countries have been reported by the EUROCARE studies. We
investigated whether similar differences by period and region existed in Switzerland.
Methods: Survival of 11 376 cases of primary invasive female breast cancer diagnosed between 1988
and 1997 and registered in seven Swiss cancer registries covering a population of 3.5 million was
analysed.
Results: Comparing the two periods 1988–1992 and 1993–1997, age-standardized 5 year relative
survival improved globally from 77% to 81%. Furthermore, multivariate analysis adjusting for age,
tumour size and nodal involvement identified regional survival differences. Survival was lowest in the
rural parts of German-speaking eastern Switzerland and highest in urbanised regions of the Latin- and
German-speaking northwestern parts of the country.
Conclusions: This study confirms that survival differences are present even in a small and affluent, but
culturally diverse, country like Switzerland, raising the issue of heterogeneity in access to care and
quality of treatment.
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Introduction
Breast cancer is the most frequent malignancy among women in
Switzerland and in developed countries. In Europe breast cancer
accounted for 13% of all newly diagnosed cases and 8% of all
cancer deaths in both sexes combined in 2004 [1]. Prognosis is
usually better than for other major cancers, and an improvement
in survival in recent decades has been reported [2–4]. This im-
provement has been variously ascribed to earlier diagnosis, in-
cluding widespread use of mammography or mass screening
campaigns, and to increasing use of effective adjuvant therapy
[5–8]. Optimal locoregional control by both surgery and radio-
therapy as well as adjuvant systemic therapy have had a major
impact on outcome [9,10].
Survival after diagnosis of cancer is one of the major outcome
measurements and key criteria for assessing quality of cancer
control related to both the preventive (early detection) and the
therapeutic level. Using data from cancer registries allows
population-based comparisons.
EUROCARE studies have been a milestone in population-
based research on survival after cancer diagnosis in Europe.
Major differences have been found in different countries and
time periods within Europe [5,11,12]. Data from two Swiss
areas, Basel and Geneva, were included in these studies. The
survival rates estimated in these two regions were favourable
compared with most other European regions. However, these
two Swiss registries cover highly urbanised populations and
therefore are not representative of the Swiss population overall.
There are marked cultural and geographical differences
within Switzerland. In addition, organisation and provision of
health care remains the responsibility of the cantons to a major
extent and thus varies between them. This is also reflected in
the cantonal differences of per capita health care expenditure.
Earlier analyses have shown clear differences in incidence
(Association of Swiss Cancer Registries: www.asrt.ch) and
mortality for many cancers between the various regions of
Switzerland [13]. Furthermore, a previous exploratory analysis
of breast cancer in two Swiss German-speaking cantons sug-
gested the existence of survival differences [14]. In the present
study we extended the investigation to other regions of the
country by including data from patients diagnosed between
1988 and 1997 in seven population-based cancer registries.
*Correspondence to: Dr J.-M. Lutz, Centre de Coordination de l’ASRT, c/o
Registre Genevois des Tumeurs, 55 Boulevard de la Cluse, 1205 Geneva,
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Materials and methods
Seven of the nine population-based Swiss cancer registries covering a pop-
ulation of 3.5 million inhabitants (48% of the Swiss population) were
involved. The cancer registries in Basel (N = 2722), Geneva (N = 2619),
Graubunden–Glarus (N = 930), St Gall–Appenzell (N = 2155), Valais (N =
1200), Zu¨rich (N = 1124) and Ticino (N = 626) provided a total of 11 376
registered cases of primary breast cancer followed for at least 5 years after
diagnosis. Cases diagnosed between 1988 or 1989 and 1997 were included in
Basel, Geneva, St Gall–Appenzell, Graubunden–Glarus and Valais, between
1993 and 1997 in Zu¨rich, and between 1996 and 1998 in Ticino. The largest
Swiss tumour registry in Zu¨rich provided survival information for a random
sample of 33% of all breast cancer patients diagnosed between 1993 and
1997. Tests for representativeness of this sample with regard to age distri-
bution and nodal status confirmed the validity of the Zu¨rich sample. All
registries used active follow-up on life status.
The data were merged into a central database after a number of quality
controls for validity and accuracy. These quality controls included routine
plausibility checks on diagnosis, morphology, topography, age, sex, dates
and checks on completeness, as well as controls on compatibility of the
variables used for staging. All participating registries contribute their data
to the International Agency of Research on Cancer (IARC) and fulfil their
quality controls. In cases with multiple tumours, only the first diagnosed
malignant tumour was included. Bilateral synchronous breast cancers were
counted as a single tumour. Cases known from their death certificate only
(DCO) and cases detected at autopsy were excluded.
Six of the seven registries have collected information on stages since
1993, all but one of those by active collection of information through mailing
of questionnaires to the treating physicians or consultation of patient records.
All used UICC rules (fourth or fifth edition). Stage data were grouped into
five EUROCARE categories : stage 1 = T1, N0, M0; stage 2 = T2–3, N0, M0;
stage 3 = T1–3, N1, M0; stage 4 = T4, any N, M0; stage 5 = any T, any N,
M1; stage 6 = unspecified stage. Data on the number of lymph nodes exam-
ined were available since 1995 from all registries. The accuracy of such
information was checked by local staff and, in addition, a standard procedure
for checking validity and concordance was conducted centrally for all data.
The Zu¨rich registry was unable to provide data on metastatic status at
diagnosis. For this reason, Cox modelling analyses for inter-cantonal com-
parisons of survival were adjusted for age (continuous), tumour size (three
categories: T0–1, T2–4, unknown), nodal involvement (three categories: N0,
N1, unknown) and number of nodes examined (five categories : zero, 1–4,
5–9, 10–14, 15+), but not for complete stage including metastatic status.
However, we used the EUROCARE five-category staging to compare fre-
quencies of stage distribution by age across all registries except Zu¨rich.
Since information about the specific cause of death was not available for
all registries, the effects of mortality from competing causes were taken into
account by computing relative survival rates, a net survival measure repre-
senting survival in the absence of other causes of death. This is the preferred
method for analysing the survival of cancer patients in population-based
studies. This survival probability is calculated using general mortality tables
related to each study period and each canton (one table per year and per
canton) provided by the Swiss Federal Statistical Office.
Age-standardised relative survival rates were calculated taking the age
distribution of the EUROCARE-2 Study breast cancer population as the
reference [12]. The confidence intervals (CIs) were calculated on the basis
of likelihood ratio statistics.
In all participating registry regions there was at least one specialised
radiotherapy service unit in operation in the mid-1990s. Oncology services
were available in all regions except Valais, where the unit came into oper-
ation only after the period of this study. The nearest available hospital-based
oncology service was about 100–150 km distant in Lausanne. However,
there were three free practising oncologists available in the canton of Valais
during the study period. The centres in some of the more rural cantons
(Graubunden–Glarus, St Gall–Appenzell, Valais, Ticino) are widespread,
and it may take longer to reach a centre, even if available, than in urban
regions (Geneva, Basel, Zu¨rich).
Results
The proportion of pathologically verified cases of breast cancer
was ‡97% in all registries. The proportion of cases eliminated as
DCO was <2% in all registries, and the same was true for cases
diagnosed at autopsy. The proportion of cases lost to follow-up
during the two periods of observation was generally low (3.6%
and 2.2% in all registries together) except in Geneva (7.3%
and 5.3%) and Graubunden–Glarus (6.7% and 3.5%). These
differences were not statistically significant. The proportion of
patients who died within the first month was 1% overall, rang-
ing from 0.6% in Basel to 2.5% in St Gall–Appenzell.
Age at diagnosis was not equally distributed between the
registries (P < 0.01 for the whole period). During the first period
(1988–1992) the differences were statistically significant for the
youngest (15–44 years) and oldest (‡65 years) age groups only,
but not for women aged 45–64 years. During the second period
(1993–1997/8), the differences were statistically significant for
all age groups (P < 0.05) except for 15–44 years. The cantons of
St Gall–Appenzell (28%), Graubunden–Glarus (24%), Ticino
(24%) and Basel (23%) had the highest proportions of cases
aged >75 years (Table 1).
Information on nodal involvement was available for all reg-
istries. In the second period, the proportion of cases with un-
known status was 10.5% overall, with some differences by
age: 4% for 15–44 years, 5% for 45–54 and 55–64 years, 7%
for 64–74 years and 28% for ‡75 years. The proportion of cases
with unknown status was £10% in patients aged <65 years in
all registries, and in all but Zu¨rich and Ticino in the age group
65–74 years. Geographical differences exist for the distribution
of nodal status at diagnosis (Table 2). They vary by age. For
instance, during the second period (1993–1997) the proportion
of nodes positive ranged from 37% (Ticino) to 54% (St Gall–
Appenzell) for age 15–44 years, from 34% (Ticino) to 48% (St
Gall–Appenzell) for age 45–54 years, from 41% (Geneva) to
56% (St Gall–Appenzell) for age 55–64 years, from 38%
Table 1. Age distribution (%) (Period 2: 1993–1997/8)
Age Basel St Gall Geneva GR–GL Valais Zu¨rich Ticino Total
15–44 10.0 11.7 11.8 14.7 13.4 10.9 12.6 11.7
45–54 21.1 20.6 24.7 20.1 26.9 24.6 20.3 22.7
55–64 22.5 19.1 25.3 18.2 23.3 23.3 22.2 22.4
65–74 23.2 21.2 18.8 22.8 17.9 20.7 20.9 20.8
75–99 23.2 27.5 19.5 24.2 18.5 20.6 24.0 22.4
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
N 1397 1114 1391 571 725 1124 626 6948
GR–GL, Graubunden–Glarus.
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(Zu¨rich) to 50% (St Gall–Appenzell) for age 65–74 years and
from 24% (Ticino) to 37% (Valais) for age ‡75 years.
Based on the most recent period of observation (1997–1998),
the number of lymph nodes examined is heterogeneous. In
German-speaking Switzerland, surgeons usually practise larger
surgical sampling than in the western part: in Basel, St Gall–
Appenzell, Zu¨rich and Graubunden–Glarus, more than 15
lymph nodes are sampled in at least 40% of cases compared
with 36% in Geneva, 23% in Ticino and 22% in Valais (P <
0.01). Overall, 39% of cases had more than 15 lymph nodes
sampled, 27% between 10 and 14, 13% between five and nine,
and 5% between five and zero. Information is missing for 19%
of cases.
Table 3 shows the geographical distribution of T stage for
all age groups combined, and Table 4 shows the stage distribu-
tion according to EUROCARE stage. Overall, stages were not
equally distributed between the registries during the period
1993–1997 (P < 0.05). For instance, Valais (12.4%) and Basel
(8.4%) had more frequent stage 4 than Graubunden–Glarus
(5.6%) and St Gall–Appenzell (5.8%) (P < 0.01). This hetero-
geneity was also observed in age-specific figures. For example,
in the age groups 55–64 years and 65–74 years, stage 1 was less
frequent in St Gall–Appenzell (19%, 18%), Valais (27%, 25%)
and Graubunden–Glarus (31%, 25%) than in Basel (37%, 29%),
Ticino (37%, 28%) and Geneva (40%, 39%) (P < 0.01), possibly
reflecting differences in screening activities. In the age group
‡75 years, stages 2, 4 and 5 differed statistically significantly
between the six registries.
Table 5 shows 1 year and 5 year age-specific and age-
standardised relative survival for cases diagnosed between
1993 and 1997. Age-specific observed (data not shown) and
relative survival tended to be better in Ticino, Basel and Geneva
than in Graubunden–Glarus and St Gall–Appenzell, with sur-
vival in Valais and Zu¨rich being intermediate. The difference
between maximum and minimum relative survival increased
with age from 2.4% (15–44 years) to 10.7% (‡75 years) for
1 year survival, and from 9.5% (15–44 years) to 16.8% (‡75
years) for 5 year survival.
Table 6 shows that age-standardised relative 5 year survival
improved between the two periods in all cantons providing
data for both periods (statistically significant for all five regis-
tries together). Table 7 shows the annual relative risk of death
in relation to Zu¨rich (reference category) after adjustment of
age, tumour size, nodal status and number of nodes sampled.
The annual risk of death is higher for St Gall–Appenzell (P <
0.05) and Graubunden–Glarus (not significant) and lower for
Basel, Geneva and Valais (P < 0.05). Ticino and Zu¨rich have
similar risks.
Relative 5 year survival by EUROCARE stage and registry
area (except Zu¨rich) is presented in Table 8. There were mod-
erate differences between registries for stage 1 (range 94–99%),
stage 2 (84–92%) and stage 3 (79–85%) cancers, respectively.
Survival ranged from 31% (Graubunden–Glarus) to 72%
(Ticino) for stage 4 (pT4 without known metastasis) and from
14% (St Gall–Appenzell) to 30% (Geneva) for stage 5 (distant
metastasis). There was also a suggestion of a difference of sur-
vival for unknown stages (ranging from 56% in Geneva to 82%
in Ticino).
Figure 1 shows observed and relative survival of all cases and
ages combined, by canton, for the period 1993–1997. Relative
survival discrepancies between cantons were larger for cases
with positive lymph nodes than for cases with negative ones
(Figure 2). Relative 5 year survival in St Gall–Appenzell and
Graubunden–Glarus was poorer than in Ticino, Geneva and
Basel for cases with both negative and positive lymph nodes.
In Zu¨rich and Valais, relative survival was close to the intercan-
tonal mean.
Table 2. Distribution of lymph node status (%), all ages
(period 2: 1993–1997/8)
Node
status
Basel St Gall Geneva GR–GL Valais Zu¨rich Ticino Total
Positive 39.3 46.1 40.8 43.6 43.4 39.1 34.3 41.0
Negative 53.0 43.4 52.9 44.3 44.8 47.8 46.5 48.4
Unknown 7.7 10.5 6.3 12.1 11.7 13.1 19.2 10.5
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
N 1397 1114 1391 571 725 1124 626 6948
GR–GL, Graubunden–Glarus.
Table 3. Distribution of T stage (%), all ages (period 2: 1993–1997/8)
T, pT Basel St Gall Geneva GR–GL Valais Zu¨rich Ticino Total
0 – – 0.4 – – – – 0.1
1 40.2 32.5 49.7 47.6 44.0 41.5 49.7 43.0
2 41.4 44.0 32.9 36.4 33.9 40.3 32.4 38.0
3 5.2 6.7 4.7 3.7 4.3 4.7 2.6 4.8
4 10.0 8.8 9.2 9.3 15.6 9.4 9.6 10.0
X 2.9 0.2 2.9 3.0 2.2 0.8 2.1 2.0
Empty 0.2 7.8 0.1 0.0 0.0 3.2 3.7 2.2
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
N 1397 1114 1391 571 725 1124 626 6948
GR–GL, Graubunden–Glarus.
Table 4. Distribution of EUROCARE stage (%) (period 2: 1993–1997/8)
EUROCARE Basel St Gall Geneva GR–GL Valais Zu¨rich Ticino Total
Stage 0 0.0 0.0 0.3 0.0 0.0 0.0 0.1
Stage 1 28.3 19.7 34.7 27.8 27.0 31.2 28.3
Stage 2 21.5 19.7 16.0 15.1 14.5 13.7 17.5
Stage 3 31.1 34.6 31.8 35.0 33.1 27.2 32.2
Stage 4 8.4 5.8 6.6 5.6 12.4 7.3 7.6
Stage 5 4.5 8.2 5.9 7.7 6.1 6.1 6.2
Unknown 6.0 11.9 4.7 8.8 6.9 14.5 8.1
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0
N 1397 1114 1391 571 725 – 626 5824
GR–GL, Graubunden–Glarus.
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Discussion
We identified differences in breast cancer survival by period and
region (cantons) in 11 376 cases diagnosed between 1988 and
1997 in Switzerland, a small and affluent, but culturally diverse,
country. Overall survival of patients diagnosed with breast can-
cer improved over time. The proportion of patients surviving at
least 5 years was 69% for those diagnosed between 1988 and
1992 (relative survival 77%), and 73% for those diagnosed be-
tween 1993 and 1997 (relative survival 81%). Age-standardised
relative survival was lower in rural regions of eastern Switzer-
land than in more urbanised western and northern regions.
These differences became minor in the second time period
for node-negative and low-stage cases, but remained present
in node-positive and advanced-stage tumours. This confirms a
previous exploratory study demonstrating less favourable sur-
vival rates for St Gall–Appenzell compared with Basel [14].
Our observation is in line with previous data from Europe [2–
4] and with data from other countries, i.e. Italy, where major
cultural differences also exist [4]. A difference in survival was
observed between the south and other parts of the country for
many tumours, including breast cancer. Additional analyses of
time trends by region also showed that there was less improve-
ment in survival in southern parts of the country. In the EURO-
CARE study, lower survival rates had been found in Denmark
than in Sweden, which are neighbouring Nordic countries. Jensen
et al. [15] compared survival of breast cancer patients from
Aarhus in Denmark and Malmo¨ in southern Sweden in a popu-
lation-based historical follow-up study of patients diagnosed
between 1983 and 1989. Even after adjustment for several pos-
sible explanatory factors (age, tumour size, intensity of lymph
node examination, regional and distant spread), as well as use of
mammography screening, a clear difference in breast cancer
survival between these two areas persisted. Differences in health
care and treatment modalities may explain some of these
remaining differences in two otherwise quite comparable areas.
In a later comparison between Danish and Swedish patient
cohorts diagnosed between 1996 and 1997 the between-country
difference tended to disappear [16]. Survival of breast cancer
patients in populations from 99 health authority regions in Eng-
land was compared in a study based on cancer registry data [17].
Even after taking socio-economic differences between the
regions into account, a statistically significant variation in breast
cancer survival between health authorities in England remained.
No tumour-specific prognostic factors were taken into account
in this study. Differences in survival by district (health boards)
were also investigated in patients from Scotland diagnosed in
1987, and the authors found statistically significantly different
survival (based on disease-specific deaths) in some districts even
after adjustment for clinical factors such as tumour stage [18].
Many factors may influence survival, including socio-
economic status, degree of urbanisation, cultural differences,
Table 5. Age-standardised and age-specific relative survival for cases
diagnosed in the period 1993–1997/8
Age at diagnosis (years) 15–44 45–54 55–64 65–74 75–99 ASRa
1 year survival
Ticino 1.00 1.00 1.00 0.97 0.92 0.98
Basel 0.98 0.99 0.97 0.98 0.95 0.97
Geneva 1.00 0.98 0.98 0.99 0.87 0.96
Zu¨rich 0.98 0.97 0.98 0.93 0.92 0.96
Graubunden–Glarus 1.00 0.96 0.98 0.92 0.90 0.95
St Gall–Appenzell 0.98 0.98 0.97 0.94 0.85 0.94
Valais 1.00 0.98 0.95 0.90 0.89 0.94
5 year survival
Ticino 0.91 0.90 0.83 0.82 0.75 0.84
Basel 0.84 0.89 0.84 0.85 0.76 0.83
Geneva 0.88 0.90 0.87 0.86 0.64 0.83
Zu¨rich 0.84 0.87 0.81 0.76 0.76 0.80
Valais 0.82 0.87 0.80 0.76 0.76 0.80
Graubunden–Glarus 0.83 0.78 0.77 0.79 0.71 0.77
St Gall–Appenzell 0.83 0.81 0.78 0.77 0.63 0.76
aStandardised to the age distribution of the EUROCARE-2 study breast
cancer population [12].
Table 6. Age-standardiseda relative survival for two different periods
of diagnosis
Relative survival 1 year 5 year 10 year
Period of diagnosis 1988–
1992
1993–
1997
1988–
1992
1993–
1997
1988–
1992
Ticino 0.98 0.84
Basel 0.97 0.97 0.80 0.83 0.69
Geneva 0.96 0.96 0.80 0.83 0.68
Zu¨rich 0.96 0.80
Valais 0.93 0.94 0.74 0.80 0.67
Graubunden–Glarus 0.96 0.95 0.74 0.77 0.56
St Gall–Appenzell 0.93 0.94 0.72 0.76 0.60
All excluding TI and ZH 0.95 0.96 0.77 0.81 0.66
aStandardised to the age distribution of the EUROCARE-2 study breast
cancer population [12].
Table 7. Annual relative risk of death for each canton compared with
Zu¨rich (period 2: 1993–1997/8)
Registries Unadjusted RR
(95% CI)
Adjusteda RR
(95% CI)
Zu¨rich (N = 1125) 1 1
Basel (N = 1397) 0.95 (0.83–1.08) 0.78 (0.66–0.92)
St Gall–Appenzell
(N = 1114)
1.32 (1.14–1.52) 1.18 (1.02–1.38)
Geneva (N = 1391) 0.81 (0.71–0.93) 0.65 (0.55–0.76)
Glarus (N = 82) 1.30 (0.89–1.91) 1.09 (0.74–1.61)
Graubunden (N = 489) 1.18 (0.97–1.42) 1.15 (0.94–1.40)
Ticino (N = 626) 0.89 (0.75–1.06) 0.97 (0.81–1.16)
Valais (N = 725) 0.97 (0.81–1.15) 0.73 (0.60–0.88)
aAdjusted on age, nodal status, tumour size and number of nodes sampled.
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patient behaviour, physicians’ attitudes, treatment, and health
care system [19–22]. While the available data do not allow
identification of specific reasons for the observed survival
differences, the observed tendency of a lower proportion of
early-stage cases in regions with less favourable survival rates
implicates differences in secondary prevention across cantons as
one potential source.
Populations from various cultural backgrounds as well as
from urban and rural regions are included in this study. Zu¨rich
and Basel are highly urbanised mainly German-speaking areas,
St Gall–Appenzell and Graubunden–Glarus are rural and German-
speaking (in Graubunden a large part of the population is
bicultural, Rumantsch and German, and a minority are Italian-
speaking). Geneva is highly urbanised and French-speaking,
Ticino is partly urban with an Italian background and Valais is
rural with a mixed cultural background, but is predominantly
French-speaking. These cultural differences are known to have
an influence on the attitude to health problems in the population
as well as in health care professionals (e.g. towards early de-
tection) [23]. There were no mammography screening pro-
grammes during the study period. However, spontaneous
screening regularly increased and official programmes started
in 1998 in the French-speaking part of Switzerland, whereas no
such programmes have been instituted so far in the German part.
The prevalence of women ever having undergone a mammog-
raphy differs substantially between the Latin- and German-
speaking parts of Switzerland [23]. These differences in behav-
iour could also explain why breast cancer incidence is higher in
the western cantons than in the eastern cantons of Switzerland:
age-standardised incidence (European) between 85 per 100 000
in St Gall–Appenzell and 127 per 100 000 in Geneva in the
period 1993–1997. Trends in mortality (European standardised
rates) over the past 20 years are also clearly different in these
two cantons: from 29 to 27 per 100 000 in St Gall–Appenzell,
and from 40 per 100 000 to 24 per 100 000 in Geneva.
The strength of this study is its population-based case ascer-
tainment through cancer registries, minimising the potential for
selection bias as observed for hospital-based survival data and
for clinical studies. The results of our study are representative
of the whole population. Methodological biases and possible
confounders affecting population-based survival comparisons
have been discussed in depth elsewhere[11,12,24], and some
of these factors are briefly mentioned below.
Incomplete registration or coding mistakes, which can bias
the survival estimates due to patient selection, is not a likely
source of bias in this study. Incidence data of all participating
registries have been approved by the IARC. The proportion of
cases known through death certificate only is <2%, and the pro-
portion of microscopically verified cases is ‡97% in all regis-
tries. In addition, cases known to registries through death
certificates only (DCO) were excluded from the analysis.
Another source of bias is incomplete follow-up. All registries
routinely used active follow-up, and specific central checking
for follow-up has been carried out for this study. Relative sur-
vival in Geneva may have been slightly overestimated because
of the migration bias described elsewhere [25], but is not likely
to explain the size of the observed survival differences.
As survival continuously improved with time in all cantons,
there could be an earlier or faster ‘downstaging’ in some
cantons. Although proportions of cases with negative lymph
nodes at diagnosis did not differ much during the two periods
Table 8. Five year relative survival by EUROCARE stage
(period 2: 1993–1997/8)
Stage St Gall Geneva GR–GL Valais Basel Ticino
1 0.98 0.99 0.97 0.94 0.97 0.98
2 0.89 0.91 0.84 0.90 0.91 0.92
3 0.79 0.85 0.79 0.84 0.80 0.81
4 0.38 0.52 0.31 0.69 0.71 0.72
5 0.14 0.30 0.24 0.27 0.25 0.24
Unknown 0.66 0.56 0.69 0.59 0.69 0.82
GR–GL, Graubunden–Glarus.
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Figure 1. (A) Observed survival and (B) relative survival of breast cancer,
all ages (period 2: 1993–1997/8).
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(49% compared with 48%, overall), frequency of early stage did,
especially for registries with poor staging during the first pe-
riod. For instance, frequency of stage 1 (all ages combined)
changed from 9% to 20% in St Gall–Appenzell and from 14%
to 27% in Valais, but only from 32% to 35% in Geneva and
from 24% to 28% in Basel, and was unchanged in Graubunden–
Glarus (28%). During the same period the proportion of un-
known stage decreased from 57% to 12% in St Gall–Appenzell
and from 6% to 5% in Geneva, and was unchanged in Basel
(6%). Therefore the simple hypothesis of a true and rapid down-
staging cannot be confirmed; we only observe a higher quality of
casenotes with a better systematic staging.
Another possible explanation is the quality of staging assess-
ment (e.g. metastasis status was not available in Zu¨rich).
Unfortunately, the group of cantons with large sampling (Basel,
St Gall–Appenzell, Zu¨rich and Graubunden–Glarus) have oppo-
site results in survival with Basel and Zu¨rich different from
St Gall–Appenzell and Graubunden–Glarus. In addition, Cox
modelling clearly showed that, even after adjustment for tumour
size, nodal involvement and number of nodes sampled, the dif-
ferences still persisted.
As mentioned above, many factors may influence survival
including differences in patient behaviour due to different cul-
tural background or socioeconomic status, differences in physi-
cians’ attitudes, treatments and access to health care. The
intercantonal differences in survival could be related to a com-
bination of such factors. The respective contributions of these
factors cannot currently be measured by data routinely collected
by all registries in Switzerland, but is the focus of ongoing
participation by Switzerland in the EUROCARE 4 and
CONCORD projects. (http://www.eurocare.it/ and http://
www.lshtm.ac.uk/ncdeu/cancersurvival/concord/index.htm).
In conclusion, we found a global improvement of survival
after diagnosis of breast cancer over a relatively short time
period. We also found differences in survival in different regions
of Switzerland, with a more favourable outcome in urbanised
regions and the western part than in the more rural regions of
the eastern part.
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